|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study显示文摘Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy. | Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen | 2021 | Cancer Communications2021，41，11： | 29 |
| 2 | Prognostic Significance of Tumor-infiltrating CD8^+ or CD3^+ T Lymphocytes and Interleukin-2 Expression in Radically Resected Non-small Cell Lung Cancer显示文摘 | Chuntao Tian Shixin Lu Qingxia Fan Weijie Zhang Shunchang Jiao Xiao Zhao Zhiyong Wu Liang Sun Liuxing Wang | 2015 | Chinese Medical Journal2015，，1： | 11 |
| 3 | Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer(ESWN 01):a prospective randomized,multicenter,open-labeled phase 3 trial显示文摘Background:The benefit of systemic treatments in esophageal squamous cell carcinoma(ESCC)which has pro-gressed after chemotherapy is still uncertain and optimal regimens based on randomized trials have not yet been established.We aimed to compare the efficacy of irinotecan plus S-1 with S-1 monotherapy in recurrent or metastatic ESCC patients who had resistance to platinum-or taxane-based chemotherapy.Methods:We conducted a prospective randomized,multicenter,open-label,phase 3 trial in 15 centers across China.Eligible patients were adults with histologically confirmed recurrent or metastatic ESCC,and were randomly assigned(ratio,1:1)to receive either irinotecan plus S-1(intravenous infusion of irinotecan[160 mg/m2]on day 1 and oral S-1[80-120 mg]on days 1-10,repeated every 14 days)or oral S-1 monotherapy(80-120 mg/day on days 1-14,repeated every 21 days)using a central computerized minimization procedure.The primary endpoint was progression-free survival(PFS).Results:Between December 23,2014 and July 25,2016,we screened 148 patients and randomly assigned 123 patients to receive either irinotecan plus S-1 regimen(n=61)or S-1 monotherapy(n=62).After a median follow-up of 29.2 months(95%confidence interval[CI]17.5-40.9 months),the median PFS was significantly longer in the irinotecan plus S-1 group than in the S-1 monotherapy group(3.8 months[95%CI 2.9-4.3 months]vs.1.7 months[95%CI 1.4-2.7 months],hazard ratio=0.58,95%CI 0.38-0.86,P=0.006).The objective response rates were 24.6%in the irinotecan plus S-1 group and 9.7%in the S-1 monotherapy group(P=0.002).The patients in the irinotecan plus S-1 group presented with increased rates of grade 3-4 leukopenia(16.4%vs.0%),neutropenia(14.8%vs.1.6%),and nausea(4.9%vs.0%).No significant difference in grade 3-4 diarrhea and no treatment-related deaths were observed in both groups.Conclusions: The combination of irinotecan with S-1 was similarly tolerable but significantly prolonged PFS compared to S-1 monotherapy as a second- or third-line treatment in patients with recurrent or metastatic ESCC. | Jing Huang Binghe Xu Ying Liu Junxing Huang Ping Lu Yi Ba Lin Wu Yuxian Bai Shu Zhang Jifeng Feng Ying Cheng Jie Li Lu Wen Xianglin Yuan Changwu Ma Chunhong Hu Qingxia Fan Xi Wang | 2019 | Cancer Communications2019，39，1： | 8 |
| 4 | Highly stretchable pseudocapacitors based on buckled reticulate hybrid electrodes显示文摘以便与高特定的电容和突出的 stretchability 开发优秀 pseudocapacitor 与在便携的未来和 bio-implantable 系统适用的另外的设备匹配,我们在三个重要方面上集中我们的研究:混合电影电极,在不同部件之间的接口,和在基于围单人赛的碳 nanotube/polyaniline (SWCNT/PANI ) 的 supercapacitors 的 stretchability 和电气化学的综合性能的 Stretchability 预先伸长的弹性体上的合成电影。由于中等的孔,弄弯的混合电影避免裂开它发生在常规可拉长的混合电极,和两个 435 F | Nan Zhang Pingshan Luan Weiya Zhou Qiang Zhang Le Cai Xiao Zhang Wenbin Zhou Qingxia Fan Feng Yang Duan Zhao YanchunWang Sishen Xie | 2014 | Nano Research2014，7，11： | 4 |
| 5 | Optical visualization and polarized light absorption of the single-wall carbon nanotube to verify intrinsic thermal applications显示文摘The predicted extraordinary properties of carbon nanotubes(CNTs)from theoretical calculations have great potential for many applications.However,reliable experimental determination of intrinsic properties at the single-tube level is currently a matter of concern,and many challenges remain because of the unhandled and nanoscale size of individual nanotubes.Here,we demonstrated a prototype to detect the intrinsic thermal conductivity of the single-wall carbon nanotube(SWCNT)and verify the significant non-resonant optical absorption behavior on tiny nanotubes by integrating the nanotube and ice into a new core-shell design.In particular,a reversible optical visualization method based on the individual suspended ultra-long SWCNT was first developed by wrapping a nanotube with ice in the cryogenic air environment.The light-induced thermal effect on the hybrid core-shell structure was used tomelt the ice shell,which subsequently acted as a temperature sensor to verify the intrinsic thermal conductivity of the core-like nanotube.More interestingly,we successfully determined for the first time the thermal response phenomenon of the tiny absorption cross section in SWCNT in the vertical-polarization configuration and the significant non-resonant absorption behavior in the parallel-polarization configuration.These investigations will provide a better understanding for the unique optical behaviors of CNT and enable the detection of intrinsic properties of various one-dimensional nanostructures such as nanotubes,nanowires,and nanoribbons. | Xiao Zhang Li Song Le Cai Xuezeng Tian Qiang Zhang Xiaoying Qi Wenbin Zhou Nan Zhang Feng Yang Qingxia Fan Yanchun Wang Huaping Liu Xuedong Bai Weiya Zhou Sishen Xie | 2015 | Light(Science & Applications)2015，4，1： | 2 |
| 6 | Effect of blocking Ras signaling pathway with K-Ras siRNA on apoptosis in esophageal squamous carcinoma cells显示文摘OBJECTIVE: To study the effect of RNAi silencing of the K-Ras gene on Ras signal pathway activity in EC9706 esophageal cancer cells. METHODS: EC9706 cells were treated in the following six groups: blank group (no transfection), negative control group (transfection no-carrier), transfection group (transfected with pSilencer-siK-ras), taxol chemotherapy group, taxol chemotherapy plus no-carrier group, taxol chemotherapy plus transfection group. Immunocytochemistry, Reverse transcription-polymerase chain reaction and western blotting were used to analyze the expression of MAPK1 (mitogen-activated protein kinases 1) and cyclin D1 in response to siRNA (small interfering RNA) transfection and taxol treatment. RESULTS: K-Ras (K-Ras gene) siRNA transfection of EC9706 esophageal squamous carcinoma cells decreased the expression of K-Ras, MAPK1 and cyclinD1 at the mRNA and protein level. Reverse transcription-polymerase chain reaction indicated that the expression levels of MAPK1 and cyclin D1 mRNAs were significantly lower in the transfection group than in the blank group (P<0.05). Western blotting showed that 72 h after EC9706 cell transfection, the expression levels of MAPK1 and cyclin D1 proteins had decreased in all groups, and the expression levels in the transfection group were significantly inhibited as compared with the blank group. Apoptosis increased significantly in the transfection group or after addition of taxol as compared with the blank group and the no-carrier group. The degree of apoptosis in the taxol plus transfection group was more severe. CONCLUSION: Apoptosis increased significantly in EC9706 esophageal carcinoma cells after siRNA-mediated inhibition of Ras signaling, with the most obvious increase observed in the transfection plus taxol chemotherapy group. Ras knockdown therefore increased cellular sensitivity to the chemotherapeutic agent, taxol. Ras knockdown also down-regulated the expression of the downstream genes, MAPK1 and cyclin D1, thus inhibiting the growth, proliferation and metabolism of esophageal cancer cells. | Xinjie Wang Yuling Zheng Qingxia Fan Xudong Zhang | 2013 | Journal of Traditional Chinese Medicine2013，33，3： | 2 |
| 7 | Insulin-Enhanced Antitumor Effect of 5-Fluorouracil in vivo显示文摘OBJECTIVE To determine if insulin treatment can enhance the antitumor effect of 5-fluorouracil(5-FU),and to explore the mech- anism of the enhancement of insulin. METHODS S180 sarcoma,H22 liver cancer and human Eca-109 esophageal cancer cells were transplanted into nude mice to evaluate the inhibitory effect on tumor growth of insulin alone or in combination with 5-FU.The levels of serum insulin-like growth factor-I(IGF-I)and insulin-like growth factor binding protein-3 (IGFBP-3)were determined. RESULTS Compared with 5-FU treatment alone,the tumor weight of H22 liver cancer and S180 sarcoma was reduced further with high,medium and low-dose insulin(0.09,0.06,0.03 U/20 g) +5-FU treatment.When a high dosage of insulin+5-FU was ad- ministered,tumor weight was significantly reduced(P<0.05).The inhibitory rate of growth of S180 sarcoma and H22 liver cancer reached 50.2% and 51.4%,respectively,which was significantly higher than 24.9% and 27.9% in the group receiving 5-FU alone (P<0.05).High,medium and low-dose insulin combined with 5-FU significantly inhibited the growth of Eca-109 cancer cells (P<0.05).Compared with the control group,the level of serum IGF-1 decreased(P<0.05),whereas the level of serum IGFBP-3 slightly increased in the 5-FU±insulin groups(P>0.05).In mice with H22 liver cancer and S180 sarcoma the IGF-1 level with high- dose insulin+5-FU treatment was significantly lower compared to treatment with 5-FU alone(P<0.05),but the difference was not significant in mice transplanted with esophageal cancer cells. CONCLUSION Insulin can enhance the anti-tumor effect of 5-FU without significantly increasing 5-FU toxicity.Although changes in the serum IGF-1 or IGFBP-3 level do not explain the mechanism of the insulin-induced enhancement on 5-FU on growth,a decrease in the level of serum IGF-1 and an increase in serum IGFBP-3 may be important in the chemotherapeutic response. | Rui Wang Qingxia Fan Xiangjie Hu Liuxing Wang Peirong Zhao Ruilin Wang | 2008 | Chinese Journal of Clinical Oncology2008，5，4： | 1 |
| 8 | 奥沙利铂联合替尼泊甙对胃癌BGC-823细胞的生长抑制和诱导凋亡的协同作用(英文)显示文摘Objective:The aim of this study was to investigate the synergistic effects of oxaliplatin and teniposide on proliferation and apoptosis of gastric cancer cell line BGC-823.Methods:MTT assay was carried to examine the inhibition rate of oxaliplatin and teniposide on gastric cancer cell line BGC-823 with various concentrations separately and associatively.The apoptosis rate of BGC-823 cells under the treatment of oxaliplatin or/and teniposide was examined by flow cytometry.The expression level of livin, an apoptosis-associated protein, was explored by western blot.Results:Oxaliplatin or teniposide could remarkably inhibit the BGC-823 gastric cancer cell growth with a dose-response manner, separately and associatively.The inhibition rate of oxaliplatin combined with teniposide on BGC-823 cells was higher than that of single oxaliplatin or single teniposide(P < 0.05), with 0.46 as combination index(CI) value.The apoptosis rates of cells treated by oxaliplatin for 12 h, 24 h and 48 h were 6.13%, 13.86% and 21.48%, respectively, while which of teniposide were 4.60%, 10.72%, 17.07%.But when the two medicines were carried associatively, the apoptosis rates for 12 h, 24 h and 48 h were 11.73%, 24.14% and 44.75%, respectively.Western blot showed that the expression level of livin was more down-regulated when cells were treated by oxaliplatin + teniposide than by oxaliplatin singly.Conclusion:The combination of oxaliplatin and teniposide can exert a synergistic effect on gastric cancer cell BGC-823. | Wang Ma Ming Gao Wei He Qingxia Fan | 2010 | The Chinese-German Journal of Clinical Oncology2010，9，3： | 1 |
| 9 | The relationship between treatment-induced hypertension and efficacy of anlotinib in recurrent or metastatic esophageal squamous cell carcinoma显示文摘Objective:In this post-hoc analysis,we evaluated anlotinib treatment-induced hypertension as a potential predictive factor of efficacy in esophageal squamous cell carcinoma(ESCC)patients.Methods:A total of 109 patients enrolled in the anlotinib group in a phase 2 trial were included.The tumor response was assessed by computed tomography at week 3,week 6,and then every 6 weeks until progressive disease was observed.The primary endpoint of the study was progression free survival(PFS).The secondary endpoints included overall survival(OS)and objective response rate(ORR).Results:In all patients,the median PFS was 3.02 months[95%confidence interval(CI):2.63–3.65 months]and the OS was 6.11 months(95%CI:4.40–7.79 months).The ORR was 7.34%(95%CI:3.22%–13.95%).A total of 59(54%)patients were diagnosed with treatment-induced hypertension(Group A),and the remaining patients(n=50,46%)were in Group B.Baseline prognostic factors were similar between the 2 groups.Patients in Group A had a longer PFS and OS and higher ORR.When stratifying patients using a previously known history of hypertension,treatment-induced hypertension was a predictor only for patients without previous hypertension,who had longer PFS[hazard ratio(HR):0.40,95%CI:0.24–0.68]and OS(HR:0.37,95%CI:0.21–0.67).Conclusions:We showed,for the first time,a correlation between treatment-induced hypertension and better prognoses in recurrent or metastatic ESCC patients treated with anlotinib,without a previously known history of hypertension.Treatment-induced hypertension may be a simple and low cost predictor for anlotinib antitumor efficacy in these patients,which may also reflect the intended target inhibition. | Yan Song Juxiang Xiao Wentao Fang Ping Lu Qingxia Fan Yongqian Shu Jifeng Feng Shu Zhang Yi Ba Yang Zhao Ying Liu Chunmei Bai Yuxian Bai Yong Tang Jie He Jing Huang | 2021 | Cancer Biology & Medicine2021，18，2： | 1 |
| 10 | Elevated serine protease HtrA1 inhibits cell proliferation, reduces invasion, and induces apoptosis in esophageal squamous cell carcinoma by blocking the nuclear factor-κB signaling pathway显示文摘 | Jin Xia Feng Wang Liuxing Wang Qingxia Fan | 2013 | Tumor Biology2013，，1： | 1 |
| 11 | Epigallocatechin?3?gallate inhibits the proliferation and migrationof human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase?2显示文摘 | Feng Wang Zhiwei Chang Qingxia Fan Liuxing Wang | 2014 | Molecular Medicine Reports2014，，： | 1 |
| 12 | Determination of sterols in tobacco leaves by gas chromatography-tandem mass spectrometry显示文摘The purpose of the study was to establish an analytical method to simultaneously determine multiple sterols in tobacco leaves rapidly and accurately.In this gas chromatography-triple quadruple tandem mass spectrometry(GC-MS/MS)based method,various conditions for sterols extraction were assessed and the instrumental operation parameters were optimized with 5α-cholane as an internal standard.Using this method,eight plant sterols,namely lanosterol,campesterol,chenodeoxycholic acid,cholesterol,β-sitosterol,stigmasterol,dihydrotachysterol and ergosterol,were separated in less than 30 min.The linear correlation coefficients were over 0.998 9,the low detection limits were in the range of 0.010 3-0.141 4 μg/g.The recoveries were from 87.30% to 115.60%,with low standard deviations.In conclusion,this method demonstrates good repeatability,accuracy,and high sensitivity,and is best suited for rapid analysis of multiple sterols in tobacco leaves. | CHEN Qiansi LIU Pingping ZHAI Niu ZHENG Qingxia XU Guoyun WANG Chen FAN Kai JIN Lifeng ZHANG Hui ZHOU Huina | 2018 | 烟草科技2018，51，A01： | 0 |
| 13 | Paclitaxel and cisplatin with or without cetuximab in metastatic esophageal squamous cell carcinoma:a randomized,multicenter phase II trial显示文摘Lack of effective targeted therapy in metastatic esophageal squamous cell carcinoma(ESCC)underscores the urgent need for identifying new treatment approaches for this challenging disease.We sought to assess the addition of cetuximab to paclitaxel-cisplatin chemotherapy for first-line treatment in patients with metastatic ESCC.In this randomized,multicenter,open-label,phase II clinical trial,patients were randomized to receive paclitaxel-cisplatin(TP)(paclitaxel[175 mg/m^(2) intravenously(i.v.)on day 1 of every 3-week cycle]and cisplatin[75 mg/m^(2) i.v.on day 1 of every 3-week cycle])and TP plus cetuximab(CTP)(cetuximab,400 mg/m^(2) i.v.on day 1 of week 1,followed by 250 mg/m^(2) weekly). | Zhihao Lu Yanqiao Zhang Qingxia Fan Yueyin Pan Da Jiang Ping Lu Jingdong Zhang Xianglin Yuan Jifeng Feng Shujun Yang Wenbin Yue Lin Zhao Yunhua Xu Jinhua Luo Lin Shen | 2022 | The Innovation2022，3，3： | 0 |
| 14 | O-GIcNAc transferase regulates centriole behavior and intraflagellar transport to promote ciliogenesis显示文摘Dear Editor,O-GIcNAcylation is a nutrient sensor that is particularly sensitive to environmental glucose(Hardiville and Hart,2014).Glucose can be converted to UDP-GIcNAc through the hexosamine biosynthetic pathway,providing a substrate for O-GIcNAcylation.Two enzymes participate in this reversible modification,O-GIcNAc transferase(OGT),which adds a single GIcNAc residue to the serine/threonine sites of proteins,and O-GIcNAcase(OGA),which removes the residue(Yang and Qian,2017). | Fan Yu Te Li Yanchao Sui Qingxia Chen Song Yang Jia Yang Renjie Hong Dengwen Li Xiumin Yan Wei Zhao Xueliang Zhu Jun Zhou | 2020 | Protein & Cell2020，11，11： | 0 |
| 15 | Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients显示文摘To the editor:Gastrointestinal(GI)cancer is the most common malignancy in China.[1]For many decades,the treatment options for GI cancers have been limited to surgery,radiotherapy,and chemotherapy.Over recent years,immune checkpoint inhibitors(ICIs)that target programmed cell death 1(PD-1),or its programmed death-ligand 1(PD-L1),have demonstrated promising efficacies and changed the treatment landscape in GI cancer.[2]However,immune-related adverse events(irAEs)can occur during ICI treatment.Furthermore,ICI-associared cardiotoxicity is a rare but potentially fatal toxic effect. | Li Yiqun Wang Yanfeng Li Ning Liang Xinjun Zhang Shu Fan Qingxia Yin Xianli Zhuang Zhixiang Liu Yunpeng Zhang Jingdong Kou Xiaoge Zhong Haijun Xu Binghe Huang Jing | 2022 | Chinese Medical Journal2022，，8： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员